14 unknown, 7 completed, 5 not yet recruiting. 10 Phase 1, 7 Phase 4, 5 Not applicable, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 10 | Unknown 6, Completed 4 |
| Phase 4 | 7 | Not yet recruiting 3, Completed 2, Unknown 2 |
| Not applicable | 5 | Unknown 3, Completed 1, Not yet recruiting 1 |
| Phase 3 | 3 | Unknown 3 |
Follow henagliflozin: new trials by email Literature Review of henagliflozin trials Research Report on henagliflozin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Henagliflozin, Retagliptin, and Metformin Extended-Release Tablets in Chinese Patients With Type 2 Diabetes Mellitus Henagliflozin, Retagliptin, and Metformin Extended-Release Tablets - T2DM (Type 2 Diabetes Mellitus) | Not yet recruiting | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | 300 | 2026-02-20 | 2026-02-27 | |
| Effect of Henagliflozin on Myocardial Fibrosis in Non-Obstructive HCM: A Randomized, Double-Blind, Placebo-Controlled Trial Using 68Ga/18F-FAPI PET/CMR Henagliflozin (SGLT2 Inhibitor), Placebo - HCM - Hypertrophic Cardiomyopathy | Not applicable | Not yet recruiting | Shanghai East Hospital | 150 | 2026-01-07 | 2025-12-19 |
| Effect of Henagliflozin on Renal Outcomes in Non-dialysis Patients With Advanced Chronic Kidney Disease : A Multicenter Prospective, Randomized Controlled Trial（HERO -aCKD） Henagliflozin 5 mg Group, Henagliflozin 10 mg Group, Conventional therapy group - Chronic Kidney Disease Stage 4 | Phase 4 | Not yet recruiting | First Affiliated Hospital of Wannan Medical College | 429 | 2025-07-10 | 2025-06-18 |
| Henagliflozin on Liver Fibrosis in Patients with MASLD and T2DM Henagliflozin 10 mg daily, Metformin 1700 mg daily, Placebo of Henagliflozin - Metabolic Dysfunction-associated Steatotic Liver Disease, Type 2 Diabetes Mellitus | Phase 4 | Not yet recruiting | Xiqiao Zhou | 190 | 2024-12-31 | 2025-01-07 |
| Henagliflozin's Impact on Prediabetes Remission Henagliflozin 5mg, Henagliflozin 10mg, Placebo - PreDiabetes, Prediabetic State | Phase 4 | Not yet recruiting | Shandong Provincial Hospital | 984 | 2024-06-01 | 2024-06-07 |
| Effects of Henagliflozin on the Brain Function in T2DM Patients With Mild Cognitive Impairment: a Randomized, Parallel Controlled Clinical Trial Henagliflozin, Gliclazide - Type 2 Diabetes Mellitus, Mild Cognitive Impairment | Not applicable | Completed | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 24 | 2024-04-01 | 2025-07-10 |
| Efficacy of Henagliflozin for Weight Loss in Obesity Without Diabetes Henagliflozin, Placebo - Obese, Weight Loss | Phase 4 | Unknown | The First People's Hospital of Changzhou | 300 | 2024-02-15 | 2024-01-22 |
| Henagliflozin in Relieving Type 2 Diabetes With Non-alcoholic Fatty Liver Disease Henagliflozin, Background medication - Type 2 Diabetes, Non-Alcoholic Fatty Liver Disease | Phase 4 | Unknown | Sir Run Run Shaw Hospital | 156 | 2024-02-15 | 2024-01-23 |
| Henagliflozin Delays the Progress of Diabetic Nephropathy Via Regulates Gut-Renal Axis Henagliflozin, Placebo - Diabetic Nephropathies | Not applicable | Unknown | Qianfoshan Hospital | 120 | 2024-01-01 | 2023-09-11 |
| The Effect of Henagliflozin and Metformin on Myocardial Tissue-level Characteristics Henagliflozin, Metformin - Obesity, Type 2 Diabetes | Not applicable | Unknown | RenJi Hospital | 64 | 2023-10-01 | 2023-09-28 |
| Henagliflozin Reducing Infarct Size After Priamry PCI in Patients With ST Segment Elevation Myocardial Infarction Henagliflozin - Myocardial Infarction, Heart Failure | Phase 4 | Completed | Qian geng | 248 | 2023-07-01 | 2025-12-02 |
| Effect of Henagliflozin on Cardiac Function in Type 2 Diabetes Patients With Chronic Heart Failure (HERO-HF) Henagliflozin 10 mg, blank control - Heart Failure | Not applicable | Unknown | Second Affiliated Hospital, Zhejiang University, School of Medicine | 1932 | 2023-04-15 | 2023-02-23 |
| Combination of Henagliflozin and Continuous Subcutaneous Insulin Infusion in T2DM Henagliflozin, Continuous Subcutaneous Insulin Infusion - Type2diabetes | Phase 4 | Completed | First Affiliated Hospital of Guangxi Medical University | 210 | 2023-03-01 | 2025-03-12 |
| Henagliflozin in Patients With Atrial Fibrillation placebo, Henagliflozin 5Mg Tab - Atrial Fibrillation | Phase 3 | Unknown | Beijing Anzhen Hospital | 100 | 2022-09-01 | 2022-05-23 |
| Drug-drug Interaction Between Simvastatin and SHR3824 SHR3824, Simvastatin - Type 2 Diabetes | Phase 1 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 12 | 2017-11-24 | 2017-11-09 |
| Efficacy and Safety of SHR3824 in Combination With Metformin in Subjects With Type 2 Diabetes Placebo, SHR3824, metformin - Type 2 Diabetes Mellitus | Phase 3 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 450 | 2017-11-02 | 2020-05-15 |
| Efficacy and Safety of SHR3824 as Monotherapy in Subjects With Type 2 Diabetes SHR3824, Placebo - Type 2 Diabetes Mellitus | Phase 3 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 450 | 2017-06-01 | 2017-05-18 |
| Safety and Pharmacokinetics/Pharmacodynamics of SHR3824 in Patients With Hepatic Impairment SHR3824 - Hepatic Impairment | Phase 1 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 32 | 2015-06-01 | 2017-05-19 |
| Safety and Pharmacokinetics/Pharmacodynamics of SHR3824 in Type 2 Diabetes Patients With Renal Insufficient SHR3824 - Renal Insufficiency,Type 2 Diabetes | Phase 1 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 24 | 2015-06-01 | 2017-05-19 |
| The Drug-drug Interaction of SHR3824 and SP2086 SHR3824, SP2086 - Type 2 Diabetes | Phase 1 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 12 | 2015-05-01 | 2015-11-25 |
Showing 20 of 26. Sign in to see all of them.
Diabetes Mellitus, Type 2 (18) · Heart Failure (3) · Obesity (2) · Arachnodactyly (1) · Atrial Fibrillation (1) · Cardiomyopathy, Hypertrophic (1) · Cognitive Dysfunction (1) · Diabetic Nephropathies (1) · Glucose Intolerance (1) · Glucose Metabolism Disorders (1) · Liver Cirrhosis (1) · Metabolic Diseases (1) · Myocardial Infarction (1) · Non-alcoholic Fatty Liver Disease (1) · Prediabetic State (1)
Jiangsu HengRui Medicine Co., Ltd. (12) · Beijing Anzhen Hospital (1) · First Affiliated Hospital of Guangxi Medical University (1) · First Affiliated Hospital of Wannan Medical College (1) · Qian geng (1) · Qianfoshan Hospital (1) · RenJi Hospital (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1) · Shandong Provincial Hospital (1) · Shanghai East Hospital (1) · Sir Run Run Shaw Hospital (1) · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (1) · The First People's Hospital of Changzhou (1) · Xinhua Hospital, Shanghai Jiao Tong University School of Medicine (1) · Xiqiao Zhou (1)
China (16)
Bimin Shi, PHD (1) · Changsheng Ma (1) · Deyong Long (1) · Hongwei Ling, MD (1) · Ji Hu (1) · Jian'an Wang, MD (1) · Jianzeng Dong (1) · Jiaqiang Zhou (1) · Jing Ma (1) · Ling Yang, MD (1) · Nan Bai, MD (1) · Ning Xu, Bachelor (1) · Xiaowei Zhu, PHD (1) · Yanmei Liu, MD (1) · Yu Liu, PHD (1)
PMID 27056772, PMID 28132924, PMID 29142025, PMID 29311992, PMID 29932506, PMID 34964875, PMID 39395826, PMID 41619161, PMID 41853855